Abstract
Two vaccines (JYNNEOS; ACAM2000) were available in the United States to prevent mpox during the 2022 clade II mpox outbreak with the majority of people receiving JYNNEOS. As part of the Biologics Effectiveness and Safety (BEST) Initiative, FDA monitored the safety of JYNNEOS using three commercial health plan claims databases supplemented with local and state Immunization Information System data. We assessed vaccine uptake, described the vaccinated population, monitored rates of 11 potential adverse events (AEs) following vaccination, and compared the observed AE rates to expected background rates. There were 152,001 JYNNEOS doses administered. Of the 92,340 people receiving at least one JYNNEOS dose, most were males (93.1%), aged 25-44 years (63.3%), lived in urban areas (98.7%), and 64.2% received a second dose. AE rates following JYNNEOS doses were similar to expected background rates. Additional safety studies of larger vaccinated populations may be needed to evaluate rare AEs including myocarditis/pericarditis.
Competing Interest Statement
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. Daniel C. Beachler reports financial support was provided by Elevance Health Inc. Daniel C. Beachler reports a relationship with Elevance Health Inc that includes: employment and equity or stocks. Djeneba Audrey Djibo and Cheryl N McMahill-Walraven are employees of CVS Health and may own stock as part of employment. Jennifer Song and Kandace Amend report financial support was provided by OptumInsight Inc. Jennifer Song and Kandace Amend report a relationship with OptumInsight Inc that includes: employment and equity or stocks. Lauren Peetluk reports financial support was provided by Optum. Lauren Peetluk reports a relationship with Optum that includes: equity or stocks. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Funding Statement
This work was supported by the U.S. Food and Drug Administration, whom were an integral part of the study design, implementation and interpretation of the analysis, writing of the report, and the decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted as part of a US FDA public health surveillance mandate under the BEST Initiative, which is part of the Sentinel Initiative. These safety surveillance activities are not considered research and therefore are exempt from institutional review board review and approval according to the requirements of 45 CFR §46;46.104(d)(2) under the 2018 Common Rule.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The study protocol was publicly posted as referenced in the manuscript before data analyses, and related documents can be made available where needed by contacting the corresponding author. De-identified participant data will not be shared without approval from the data partners.
